Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.

Article Details

Citation
Copy to clipboard

Afra TP, Razmi TM, Dogra S

Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.

Indian Dermatol Online J. 2019 Jan-Feb;10(1):1-12. doi: 10.4103/idoj.IDOJ_437_18.

PubMed ID
30775293 [ View in PubMed
]
Abstract

Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from Drug Controller General of India for marketing in India in 2017. The drug has drawn much attention from the practising dermatologists for its commendable safety profile and prescription convenience. Introduced initially as an orally administered small molecule in psoriasis patients, the drug has now been used in various other indications as evident by the recent surge in literature for its off-label uses. Being a relatively new drug in the treatment armamentarium of psoriasis and other inflammatory dermatoses; in this review, we will discuss various practical aspects of prescribing oral apremilast, based on the current and emerging literature.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
ApremilastPhosphodiesterase isozyme 4ProteinHumans
Yes
Antagonist
Details